Burden of symptoms could guide NSCLC pemetrexed use
Symptom burden and performance status may help identify the patients with non-squamous non-small-cell lung cancer who are likely to respond to maintenance pemetrexed therapy, phase III trial findings suggest.
Source: MedWire News - Respiratory - Category: Respiratory Medicine Source Type: news
More News: Alimta | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine